The Undervalued Stock That Superinvestors Are Loading Up On

As part of the weekly research here at The Acquirer’s Multiple we’re always interested in investing gurus who hold the same stocks that appear in our Acquirer’s Multiple Stock Screeners, based on their latest 13F’s. Investors such as Warren Buffett, Joel Greenblatt, Carl Icahn, Jim Simons, Prem Watsa, Jeremy Grantham, Seth Klarman, Ray Dalio, and Howard Marks.

While doing this research we’ve also uncovered a number of common stocks that investing gurus have recently bought, or continuing to hold in their portfolios, according to their latest 13f’s. So we’re now providing a new weekly feature article called ‘One Stock Superinvestors Are Buying’. This week we’ll take a look at:

Bristol-Myers Squibb Co (BMY)

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.

A quick look at the price chart below for the company shows us that the stock is down 31.61% in the past twelve months.

BMY data by YCharts

Superinvestors who recently bought, or continue to hold the stock, according to their latest 13Fs include:

(Shares)

Rich Pzena – 5,592,816

Ken Griffin – 2,986,042

Israel Englander – 2,487,593

Jim Simons – 2,432,166

John Rogers – 979,748

Joel Greenblatt – 259,150

Ken Fisher – 223,431